Aurobindo Pharma USA, Inc, a wholly owned subsidiary of Aurobindo Pharma Limited, has received approval from the US Federal Trade Commission (FTC) to proceed with its acquisition of Lannett Company LLC, clearing the final regulatory hurdle for the transaction. The acquisition, valued at $250 million on a cash-free, debt-free basis, including normalized working capital, is expected to be completed before the end of June 2026.
The acquisition marks a significant strategic milestone for Aurobindo Pharma as it strengthens its presence in the US generic pharmaceutical market while expanding its portfolio of complex generic medicines and non-opioid controlled substances. Headquartered in Pennsylvania, Lannett is a well-established generic pharmaceutical company with expertise in the development, manufacturing and commercialization of complex generic products. The transaction will also add Lannett’s manufacturing facility in Seymour, Indiana, to Aurobindo’s global production network, significantly enhancing its manufacturing footprint in the United States.
The Seymour facility has the capacity to manufacture approximately four billion doses annually, providing substantial production scalability to meet growing demand. The expanded manufacturing base is expected to support ongoing efforts to strengthen domestic pharmaceutical production and improve supply chain resilience in the United States.
Beyond expanding manufacturing capabilities, the acquisition is expected to deliver immediate financial benefits. Aurobindo Pharma anticipates the transaction will be earnings accretive from the outset while generating operational efficiencies through cost optimisation, streamlined administrative functions and manufacturing synergies. The addition of Lannett’s differentiated product pipeline is also expected to strengthen the company’s long-term growth prospects in specialised generic therapies.
Swami S Iyer, Chief Executive Officer of Aurobindo Pharma USA, said the acquisition represents an important strategic opportunity that will accelerate the company’s growth in the US market. He noted that the transaction enhances domestic manufacturing capabilities, expands the portfolio in complex non-opioid controlled substances and creates long-term value through operational integration and pipeline expansion. He added that Aurobindo looks forward to welcoming the Lannett team and leveraging the combined strengths of both organisations to improve patient access to essential medicines.
Tim Crew, Chief Executive Officer of Lannett Company, said joining Aurobindo Pharma opens a new chapter for the company. He noted that Lannett has built a long-standing reputation for providing affordable generic medicines, and the partnership will enable its products to reach more patients through Aurobindo’s global resources and market presence.
Headquartered in Hyderabad, Aurobindo Pharma Limited is one of India’s leading integrated pharmaceutical companies, with operations spanning more than 150 countries. The company develops, manufactures and markets generic medicines, specialty pharmaceuticals and active pharmaceutical ingredients through a global network of over 30 manufacturing and packaging facilities approved by leading international regulatory authorities. The latest acquisition further strengthens Aurobindo’s position as a global supplier of high-quality, affordable medicines while expanding its manufacturing capabilities in one of its largest international markets.
